Grant: Collaborative Health Research Projects
Queen's University
$54,243.00
Preclinical Development of Natural Product-Based Agents as Anti-Cancer Drugs
FY 2014-15
Summary
Cancer metastases (the spreading of cancer cells from one organ or tissue to another) are ultimately the cause of death in90 percent of cancer patients. Therefore, the need for drugs capable of interfering with this process is enormous. As theactin cytoskeleton is the key cellular machinery responsible for the morphological changes in cancer cells that facilitate theirability to metastasize, our research project will develop new chemotherapeutic agents to defeat the contribution of actin tothe spread of cancer. Using our detailed knowledge of potent natural inhibitors of actin, we will design and synthesize cancertargeting versions of these inhibitors by joining them to cancer-seeking antibodies. These antibody-drug conjugates (ADCs)will maximize the cancer killing potential of the therapeutic by allowing the actin-inhibiting component to be taken up by thecancer cells with precision, before they have a chance to form secondary tumours. In doing so, these agents will reducemany of the common side-effects associated with cancer chemotherapies, and will diminish cancer burden and mortality forCanadians.
Program
Collaborative Health Research Projects
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
462231-2014
Name nom
Allingham, John
Department département
Biomedical and Molecular Sciences
Organization id
29
Institution établissement
Queen's University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2014
Competition year année de concours
2014
Award amount
54243
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
1
Nb partie
3
Application title
Preclinical Development of Natural Product-Based Agents as Anti-Cancer Drugs
Keyword
NSERC
Application summary
Cancer metastases (the spreading of cancer cells from one organ or tissue to another) are ultimately the cause of death in90 percent of cancer patients. Therefore, the need for drugs capable of interfering with this process is enormous. As theactin cytoskeleton is the key cellular machinery responsible for the morphological changes in cancer cells that facilitate theirability to metastasize, our research project will develop new chemotherapeutic agents to defeat the contribution of actin tothe spread of cancer. Using our detailed knowledge of potent natural inhibitors of actin, we will design and synthesize cancertargeting versions of these inhibitors by joining them to cancer-seeking antibodies. These antibody-drug conjugates (ADCs)will maximize the cancer killing potential of the therapeutic by allowing the actin-inhibiting component to be taken up by thecancer cells with precision, before they have a chance to form secondary tumours. In doing so, these agents will reducemany of the common side-effects associated with cancer chemotherapies, and will diminish cancer burden and mortality forCanadians.
